摘要
目的观察肝动脉化疗栓塞联合经脾动脉间接性门静脉内灌注化疗药物治疗原发性肝癌的疗效,并探讨患者血清细胞因子的变化。方法30例原发性肝癌患者行肝动脉化疗栓塞,40例行肝动脉化疗栓塞联合经脾动脉间接性门静脉内灌注化疗药物,采用ELISA法测定患者术后血清TNF-α、IL-2、sIL-2R和VEGF水平。结果两组治疗后血清TNF-α、sIL-2R和VEGF水平均较治疗前降低(P<0.01),而IL-2升高(P<0.01);双灌注治疗后1、2和3年生存率分别为72.5%、55%和25%,而TACE治疗组则分别为60%、30%和6.7%,两组间存在显著性差异(P<0.05)。结论双灌注介入治疗原发性肝癌能改善机体的免疫状况,提高疗效。
Objective To study the therapeutic effects of transcatheter arterial ehemoembolization combined with lienalis infusion indirectly to portal vein in treating patients with primary liver cancer. Methods 30 patients with PLC underwent transcatheter arterial chemoembolization treatment,while 40 underwent transcatheter arterial chemoembolization combined with lienalis infusion to portal vein. The serum levels of TNF-α,IL-2,slL-2R and VEGF were assessed by ELISA. Results The serum levels of TNF-α,slL-2R as well as the VEGF levels in the two groups decreased （P〈0.01）, while IL-2 increased （P〈0.01）after treatment;The 1,2 and 3 year survival rates of patients with transeatheter arterial ehemoembolization combined with lienalis infusion to portal vein were 72.5%,55% and 25%,higher than that of single TACE therapy group （60%,30% and 6.7%,respectively,P〈0.05）. Conclusion Transeatheter arterial chemoembolization combined with lienalis infusion in treating patients with primary liver cancer can improve the immune function and enhance the curative effect.
出处
《实用肝脏病杂志》
CAS
2009年第6期432-434,共3页
Journal of Practical Hepatology
